Ten years EULAR Scleroderma Research and Trials (EUSTAR): What has been achieved?

Annals of the Rheumatic Diseases

Volumn 73, Issue 2, 2014, Pages 324-327

  Müller Ladner, Ulf ^a   Tyndall, Alan ^b   Czirjak, Laszlo ^c   Denton, Christopher ^d   Matucci Cerinic, Marco ^e  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Felix Platter Spital   (Switzerland)

^c UNIVERSITY OF PÉCS   (Hungary)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; EUROPE; EUROPEAN LEAGUE AGAINST RHEUMATISM SCLERODERMA TRIALS AND RESEARCH; HEALTH PROGRAM; HISTORY OF MEDICINE; HUMAN; MEDICAL RESEARCH; MEDICAL SOCIETY; ORGANIZATIONAL DOWNSIZING; ORGANIZATIONAL EFFICIENCY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL COMPETENCE; PROFESSIONAL KNOWLEDGE; PROGRAM DEVELOPMENT; RHEUMATIC DISEASE; SCLERODERMA; SYSTEMIC SCLEROSIS;

EID: 84891744888     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203997     Document Type: Article

References (35)

1. Tyndall A, Mueller-Ladner U, Matucci-Cerinic M. Systemic sclerosis in Europe: first report from the EULAR Scleroderma Trials And Research (EUSTAR) group database. Ann Rheum Dis 2005;64:1107.
2. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809-15.
3. Tyndall A, Muller-Ladner U, Matucci-Cerinic M. The EULAR Scleroderma Trials and Research Group (EUSTAR): an international framework for accelerating scleroderma research. Curr Opin Rheumatol 2008;20:703-6.
4. Kucharz EJ. The assessment of the patient with systemic sclerosis clinical course of the EUSTAR Budapest, January 13-16, 2005. Pol Arch Med Wewn 2005;114:1037-8.
5. Czirjak L, Nagy Z, Aringer M, et al. The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis 2007;66:966-9. (Pubitemid 46999803)
6. Ionescu R, Rednic S, Damjanov N, et al. Repeated teaching courses of the modified Rodnan skin score in systemic sclerosis. Clin Exp Rheumatol 2010;28(2 Suppl 58):S37-41.
7. Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620-8.
8. Avouac J, Kowal-Bielecka O, Landewe R, et al. European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research. Ann Rheum Dis 2009;68:629-34.
9. Walker UA, Tyndall A, Czirjak L, et al. Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann Rheum Dis 2009;68:856-62.
10. Matucci-Cerinic M, Allanore Y, Czirjak L, et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis 2009;68:1377-80.
11. Becker MO, Muller-Ladner U, Riemekasten G. Towards an implementation of guidelines for the therapy of systemic sclerosis (scleroderma): between desire and reality. Z Rheumatol 2010;69:310-17.
12. Meier FM, Frommer KW, Dinser R, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2012;71:1355-60.
13. Walker KM, Pope J; Scleroderma Clinical Trials Consortium; Canadian Scleroderma Research Group. Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis. J Rheumatol 2011;38:1326-8.
14. Galluccio F, Walker UA, Nihtyanova S, et al. Registries in systemic sclerosis: a worldwide experience. Rheumatology 2011;50:60-8.
15. Distler JH, Jordan S, Airo P, et al. Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. Clin Exp Rheumatol 2011;29(2 Suppl 65):sS40-5.
16. Elhai M, Meunier M, Matucci-Cerinic M, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 2013;72:1217-20.
17. Fransen J, Popa-Diaconu D, Hesselstrand R, et al. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis 2011;70:1788-92.
18. Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007;66:754-63. (Pubitemid 46846694)
19. Avouac J, Fransen J, Walker UA, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 2011;70:476-81.
20. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747-55.
21. Allanore Y, Borderie D, Airo P, et al. Lack of association between three vascular endothelial growth factor gene polymorphisms and systemic sclerosis: results from a multicenter EUSTAR study of European Caucasian patients. Ann Rheum Dis 2007;66:257-9. (Pubitemid 46226065)
22. Rozman B, Cucnik S, Sodin-Semrl S, et al. Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study. Ann Rheum Dis 2008;67:1282-6.
23. Distler JH, Allanore Y, Avouac J, et al. EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. Ann Rheum Dis 2009;68:163-8.
24. Allanore Y, Meune C, Vonk MC, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 2010;69:218-21.
25. Avouac J, Walker U, Tyndall A, et al. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol 2010;37:1488-501.
26. Alizadeh BZ, Broen J, Rueda B, et al. Functional variants of Fc gamma receptor (FCGR2A) and FCGR3A are not associated with susceptibility to systemic sclerosis in a large European Study (EUSTAR). J Rheumatol 2010;37:1673-9.
27. Beyer C, Distler JH, Allanore Y, et al. EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. Ann Rheum Dis 2011;70:1178-82.
28. Wipff J, Coriat R, Masciocchi M, et al. Outcomes of Barrett's oesophagus related to systemic sclerosis: a 3-year EULAR Scleroderma Trials and Research prospective follow-up study. Rheumatology 2011;50:1440-4.
29. Foocharoen C, Distler O, Becker M, et al. Clinical correlations of hypocomplementaemia in systemic sclerosis: an analysis of the EULAR Scleroderma Trial and Research group (EUSTAR) database. Scand J Rheumatol 2012;41:243-6.
30. Koumakis E, Wipff J, Dieude P, et al. TGFβ receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: results from a multicentre EUSTAR study of European Caucasian patients. Ann Rheum Dis 2012;71:1900-3.
31. Heijnen IA, Foocharoen C, Bannert B, et al. Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study. Clin Exp Rheumatol 2013;31(Suppl 36):96-102.
32. Foeldvari I, Tyndall A, Zulian F, et al. Juvenile and young adult-onset systemic sclerosis share the same organ involvement in adulthood: data from the EUSTAR database. Rheumatology 2012;51:1832-7.
33. Hugle T, Schuetz P, Daikeler T, et al. Late-onset systemic sclerosis-a systematic survey of the EULAR scleroderma trials and research group database. Rheumatology 2011;50:161-5.
34. Schneeberger D, Tyndall A, Kay J, et al. Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database. Rheumatology 2013;52:560-7.
35. Saketkoo LA, Escorpizo R, Keen KJ, et al. EUSTAR. International classification of functioning, disability and health core set construction in systemic sclerosis and other rheumatic diseases: a EUSTAR initiative. Rheumatology 2012;51:2170-6.